Hostname: page-component-745bb68f8f-hvd4g Total loading time: 0 Render date: 2025-01-12T11:52:29.291Z Has data issue: false hasContentIssue false
  • English
  • Français

Briefs from the Fields of Neurology & Neuropsychiatry

Published online by Cambridge University Press:  07 November 2014

Get access Rights & Permissions [Opens in a new window]

Abstract

An abstract is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.
Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'
Type
Nota Bene
Information
CNS Spectrums , Volume 3 , Issue 3: Autism: Emerging Concensus , March 1998 , pp. 20 - 21
Copyright
Copyright © Cambridge University Press 1998

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

REFERENCES

1.Thyrum, P, Yeh, C, Potkin, S, et al. Safety and tolerability of switching from conventional antipsychotic therapy to seroquel (quetiapine fumarate) followed by abrupt withdrawal from seroquel. Poster presentation at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hawaii, December, 1997.Google Scholar
2.Arvantis, L, Miller, B, Kowalcyk, B. Efficacy of seroquel (quetiapine fumarate) in affective symptoms of schizophrenia. Poster presentation at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hawaii, December, 1997.Google Scholar
3.Goldstein, J, Arvantis, L, Cantillon, M. Low incidence of reproductive/hormonal side effects with seroquel (quetiapine fumarate) is supported by its lack of elevation of plasma prolactin concentration. Poster presentation at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hawaii, December, 1997.Google Scholar
4.Cantillon, M, Arvantis, L, Miller, B, Kowalcyk, B. Seroquel (quetiapine fumarate) reduces hostility and aggression in patients with acute schizophrenia. Poster presentation at the American College of Neuropsychopharmacology (ACNP) Annual Meeting, Hawaii, December, 1997.Google Scholar